Anatara Lifesciences Ltd
AASX:ANR0.01
AUD
0.00
(0.00%)
ISIN
AU000000ANR0
Return %
Stock
S&P 500
1Y
-43.75
14.39
3Y
-66.94
81.42
5Y
-93.18
68.62
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- David Lionel Brookes
- Full Time Employees
- 7
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 81 Flinders Street Adelaide SA Australia 5000
- IPO Date
- Oct 16, 2014
- Website
- anataralifesciences.com
- Similar Companies
- Business
- Anatara Lifesciences Ltd (ASX:ANR) develops and commercializes evidence-based, non-antibiotic oral solutions for gastrointestinal diseases in humans and animals; core human health products include Gastrointestinal ReProgramming (GaRP), a proprietary microbiome-targeted complementary medicine formulated with bromelain and synergistic generally recognized as safe (GRAS) components to address irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) via gut-brain axis modulation and microbiome homeostasis; animal health offerings comprise Detach, a commercialized therapy for post-weaning diarrhea in piglets offering protection comparable to zinc oxide antimicrobials, BONIFF, a dry-feed formulation of Detach, and ANR-pf, an enriched poultry solution administered in water. The company, founded in 2010 and headquartered at Level 8, 81 Flinders Street, Adelaide, South Australia, operates primarily in Australia with a focus on building a human health pipeline through proprietary technology and strategic partnerships; it targets unmet needs in complex gastrointestinal conditions affecting patients with IBS, obesity comorbidities, and livestock producers seeking antibiotic alternatives. Recent developments include completion of the Phase II GaRP-IBS trial in early 2025, which confirmed safety and tolerability with positive secondary outcomes such as statistically significant improvements in adequate relief (p=0.004) and anxiety scores despite missing the primary IBS Severity Scoring System endpoint, prompting efforts to maximize GaRP value through commercial discussions; advancement of a new anti-obesity project with in-vivo preclinical studies underway at the University of Newcastle to develop an oral adjunct for weight loss maintenance and rebound prevention post-GLP-1 therapies; securing AU$1.2 million via a two-tranche placement in September 2025 to fund the anti-obesity program, working capital, and due diligence on opportunities; appointment of biotech veteran Dirk van Dissel as Non-Executive Director in September 2025 amid board renewal; and an Australian patent grant for GaRP earlier in the year.